Emergency Department Visits by Children and Adolescents for Antipsychotic Drug Adverse Events
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
i

Superseded

This Document Has Been Replaced By:

i

Retired

This Document Has Been Retired

i

Up-to-date Information

This is the latest update:

Emergency Department Visits by Children and Adolescents for Antipsychotic Drug Adverse Events
Filetype[PDF-108.28 KB]


No Related Documents.

You May Also Like:

  1. Filetype[PDF - 580.38 KB]
    Personal Author:
    Shimabukuro, Tom T.; Nguyen, Michael; Martin, David; DeStefano, Frank;
    Published Date:
    Jul 22 2015
    Source:
    Vaccine. 33(36):4398-4405
    Description:
    The Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) conduct post-licensure vaccine safety monitoring using the Vaccine Adverse Event Reporting System (VAERS), a spontaneous (or passive) reporting syste...
    File Type:
    Filetype[PDF - 580.38 KB]
  2. Filetype[PDF - 422.00 KB]
    Personal Author:
    Lovegrove, Maribeth C.; Mathew, Justin; Hampp, Christian; Governale, Laura; Wysowski, Diane K.; Budnitz, Daniel S.;
    Published Date:
    September 15 2014
    Source:
    Pediatrics. 134(4):e1009-e1016
    Description:
    BackgroundEmergency department visits and subsequent hospitalizations of young children following unsupervised ingestions of prescription medications are increasing despite widespread use of child-resistant packaging and caregiver education efforts. ...
    File Type:
    Filetype[PDF - 422.00 KB]
  3. Filetype[PDF - 66.44 KB]
    Personal Author:
    Moro, Pedro L.; Winiecki, Scott; Lewis, Paige; Shimabukuro, Tom T.; Cano, Maria;
    Published Date:
    October 27 2015
    Source:
    Vaccine. 33(48):6684-6688
    Description:
    Background:In November 2012, the first cell cultured influenza vaccine, a trivalent subunit inactivated influenza vaccine (Flucelvax®, ccIIV3), was approved in the US for adults aged ≥18 years.Objective:To assess adverse events (AEs) after ccIIV3 ...
    File Type:
    Filetype[PDF - 66.44 KB]
  4. Filetype[PDF - 1.53 MB]
    Personal Author:
    Geller, Andrew I.; Shehab, Nadine; Lovegrove, Maribeth C.; Kegler, Scott R.; Weidenbach, Kelly N.; Ryan, Gina J.; Budnitz, Daniel S.;
    Published Date:
    May 2014
    Source:
    JAMA Intern Med. 174(5):678-686
    Description:
    ImportanceDetailed, nationally-representative data describing high-risk populations and circumstances involved in insulin-related hypoglycemia and errors (IHEs) can inform approaches to individualizing glycemic targets.ObjectiveDescribe U.S. burden, ...
    File Type:
    Filetype[PDF - 1.53 MB]
  5. Filetype[PDF - 102.10 KB]
    Personal Author:
    Miller, Elaine R.; Moro, Pedro L.; Cano, Maria; Shimabukuro, Tom;
    Published Date:
    May 23 2015
    Source:
    Vaccine. 33(29):3288-3292
    Description:
    Vaccines are rigorously tested and monitored and are among the safest medical products we use. Millions of vaccinations are given to children and adults in the United States each year. Serious adverse reactions are rare. However, because of the high ...
    File Type:
    Filetype[PDF - 102.10 KB]